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Abstract
Background: Estimating quality of life (QoL) in patients with breast cancer is of importance in assessing treatment
outcomes. Adjuvant endocrine therapy is widely used for hormone receptor-positive (HR+) early-stage breast
cancer (EBC), and evidence suggests that aromatase inhibitors (AIs) may improve QoL for these patients. This
study evaluated QoL in postmenopausal Chinese patients with HR+ EBC taking AIs.
Methods: This was a prospective, multicenter, and observational study that had no intent to intervene in the
current treatment of recruited patients. Eligible patients were recruited within 7 days of beginning adjuvant
treatment with AIs. The Functional Assessment of Cancer Therapy-Breast (FACT-B) scale was used to evaluate
the patients’ QoL. Data were collected at baseline and at 6, 12, 18, and 24 months.
Results: From June 2010 to October 2013, a total of 494 patients with HR+ EBC were recruited from 21 centers.
There was a 7.51-point increase in the patients’ mean FACT-B trial outcome index (TOI), from 90.69 at baseline
to 98.72 at 24 months (P < .0001). The mean TOI scores at baseline, 6, 12, and 18 months were 90.69, 94.36, 97.71, and
96.75, respectively (P < .0001, for all). The mean (FACT-B) emotional well-being subscale scores at baseline, 6, 12, 18, and
24 months were 16.32, 16.55, 17.34 (P < .0001), 17.47 (P < .0001), and 17.85 (P < .0001), respectively, and social well-being
scores were 18.61, 19.14 (P < .04), 19.35 (P < .008), 18.32, and 18.40, respectively. In the mixed model, baseline
TOI, clinical visits, prior chemotherapies, age group, and axillary lymph-node dissection presented statistically
significant effects on the change of FACT-B TOI and FACT-B SWB, whereas only baseline TOI, clinical visits, and
prior chemotherapies presented statistically significant effects on the change of FACT-B EWB. FACT-B TOI, being
the most pertinent and precise indicator of patient-reported QoL, demonstrated significant changes reflecting
clinical benefit of adjuvant AIs endocrine therapy in the QoL of HR + EBC patients.
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Conclusions: The study demonstrated significant improvements in the long-term QoL of postmenopausal
Chinese patients with HR+ EBC at 6, 12, 18, and 24 months after starting treatment with AIs. The current study
indicates improved long-term QoL with AI adjuvant treatment, which will aid clinicians in optimizing treatment
to yield effective healthcare outcomes.
Trial registration: Clinicaltrials.gov NCT01144572
Keywords: Quality of life, Prospective, Functional Assessment of Cancer Therapy-Breast, Trial outcome index,
Hormone receptor-positive early-stage breast cancer postmenopause, Adjuvant, Aromatase inhibitors, Early breast cancer
Background
Breast cancer is the most common cancer in women
worldwide, with nearly 1.7 million new cases diagnosed
in 2012, representing about 12 % of all new cancer cases
and 25 % of all cancers in women [1]. China accounts
for nearly 12.2 % of all newly diagnosed breast cancer
cases and about 9.6 % of all deaths from breast cancer
worldwide [2]. In the past two decades, although the in-
cidence of breast cancer has steadily increased, the death
rate from the disease has declined [3]. Moreover, aware-
ness of patients’ quality of life (QoL) during treatment is
increasing, making it important for physicians and pa-
tients to consider therapeutic efficacy, safety of medical
interventions, and QoL when selecting a treatment pro-
gram. In addition, health-related QoL (HRQoL) is now
being considered as an important end point in cancer
clinical trials, which could contribute to improved treat-
ment outcomes [4, 5].
Because various studies have consistently demonstrated
superior efficacy and safety of the third-generation aroma-
tase inhibitors (AIs) compared with those of tamoxifen
alone in postmenopausal women with ER (+) breast cancer
[6, 7], AIs are widely administered as standard adjuvant
endocrine therapy in this population [8]. Previous re-
searches suggested that treatment of patients with
early-stage breast cancer (EBC) with third-generation AIs
(e.g., anastrozole, letrozole, and exemestane) may improve
their QoL [6–9]. However, this therapy is associated with
persistent side effects and toxicity, which lead to negatively
impact the patient’s QoL [10].
The Functional Assessment of Cancer Therapy-Breast
(FACT-B), developed by Rush-Presbyterian-St. Luke’s
Medical Center, Chicago, United States, is a widely used
international scale to assess the QoL of patients with
cancer [11, 12]. The use of such internationally consist-
ent and validated scales to evaluate the QoL of Chinese
patients will help improve the understanding of breast
cancer outcomes. Specifically, they should enable physicians
and patients to more clearly understand the long-term ef-
fects of AI therapy in breast cancer while making important
treatment decisions. To date no nationwide, prospective,
multicenter study has been available in China to evaluate
the QoL of postmenopausal patients with early-stage breast
cancer (EBC) positive (+) for hormone receptors (HR)
treated with adjuvant therapy with AIs. It is of vital
importance to evaluate the quality of life of Chinese
patients using an internationally accepted method, so
that the Chinese physicians are better knowledgeable
about the effects of AIs on the long-term therapy when
making therapeutic decisions. Because QoL studies can
further indicate the directions needed for efficient treat-
ment of cancer, the current study was conducted to evalu-
ate the QoL of postmenopausal patients with HR (+) EBC
receiving adjuvant treatment with AIs [13, 14].
Methods
Study design
This was the first prospective, multicenter, observational,
non-interventional study in Chinese postmenopausal
women [HR (+) and EBC] undergoing adjuvant treatment
with AIs. There was no intent to intervene in the current
treatment of the recruited patients (NCT01144572).
Participants
The following were the screening criteria: postmeno-
pausal women, age ≤70 years, histologically documented
HR (+) EBC, currently on adjuvant endocrine therapy
with AIs and indications approved by the State Food and
Drug Administration (SFDA), or AI adjuvant therapy
started within the past 7 days. Women were eligible to
be included in the study if they had simple mastectomy,
breast-conserving surgery, or axillary lymph node dissec-
tion or sampling. Patients were excluded from the ana-
lysis if they were disinterested in participating, unable to
adhere to the trial requirements for any reason, or were
using AIs not approved by the SFDA for initial adjuvant
endocrine therapy for EBC. Written informed consent
for the data collection was obtained at the clinic visit
after eligibility requirements were confirmed by the in-
vestigator. At any point during the study, patients could
discontinue from the final analysis if it was their own
decision, they had discontinued previous AI medication,
or they had a documented evidence of disease relapse or
progression.
The study was performed in accordance with Declar-
ation of Helsinki and Good Clinical Practice Guidelines,
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with approval obtained from each center’s independent
ethics committee.
Study objective
The primary objective was to evaluate overall QoL in
postmenopausal patients with HR(+) EBC during adju-
vant treatment with AIs by assessing the change in the
trial outcome index (TOI) of the FACT-B questionnaire
from baseline to 24 months. The secondary objective
was to evaluate the QoL in the same population during
adjuvant treatment with AIs by examining FACT-B
questionnaire results at several time points (baseline, 6,
12, and 18 months) on three FACT-B measures: TOI,
emotional well-being (EWB) subscale scores, and social
well-being (SWB) subscale scores. In addition, the fac-
tors affecting the QoL of patients with breast cancer
were also determined.
Data collection
Data for demography and pathological examination for
breast cancer were obtained for all the patients included
in the analysis. Demographic parameters recorded were
age, ethnic background, height, weight, basal metabolic
index, and World Health Organization (WHO) perform-
ance status score. Pathological examination for breast can-
cer included assessment of the primary site, histological
type, histological grading, and TNM stage. In addition,
data were recorded for status of estrogen and progester-
one receptors, history of breast cancer surgery, history of
prior chemotherapy or radiotherapy, and use of AIs.
Quality of life assessment
QoL was assessed using the FACT-B questionnaire from
baseline to 6, 12, 18, and 24 months. The TOI (sum of
the physical well-being, functional well-being, and breast
cancer–specific questions in the FACT-B) was regarded
as the primary end point. An increase in TOI of more
than 5 points from baseline, disease progression, or death
was considered a clinically meaningful improvement in
QoL. FACT-B instrument uses a 5-point rating scale, in-
cluding measures for physical, social/family, emotional,
and functional well-being. The instrument was used to
inquire respondents on how true each statement was for
the past 7 days and rate them. Response scales ranged
from 0 (not at all) to 4 (very much). A one-on-one dis-
cussion was scheduled to collect data on demographic
characteristics and QoL.
Statistical methods
The sample size was not formally calculated as this was
a cohort study and there was no formal comparison be-
tween the groups. It was projected that 500 patients would
Fig. 1 Study flow chart
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be enrolled within 3 years given the patient pool capacity in
the participating sites. The primary QoL analysis, inclusive
of all available questionnaires, was based on the patients
who completed the informed consent form (ICF) and had
one clinical visit included in the final analysis. The analysis
was performed using the MIXED procedure of the SAS
statistical software (SAS Institute, Cary, North Carolina,
USA), which has the advantage of handling missing data
without any imputation of missing values, provided that
data are missing at random. Baseline covariates such as
TOI score, prior chemotherapy (yes/no), age group, mast-
ectomy (yes/no), and axillary clearance (yes/no) were in-
cluded in the model regardless of statistical significance.
This repeated measures analysis also included time from
baseline, as both fixed and random polynomial effects, to
allow patient-specific time trends and intercepts (described
via random effects) to vary around an overall average trend
and intercept (described via the fixed effects). The results of
the analyses are presented in terms of adjusted means, asso-
ciated confidence intervals (CIs), and P values. The mean
score change from baseline was calculated for each patient
with valid baseline questionnaires.
Results
Patient disposition
From June 2010 to October 2013, a total of 494 patients
were enrolled in the study; of these patients, 453
(91.7 %) completed the study and 41 (8.3 %) prematurely
discontinued from the study as a result of loss to follow-
up (5.1 %), disease relapse/progression (1.2 %), failure to
adhere to inclusion/exclusion criteria (0.6 %), voluntarily
discontinuation (0.4 %), cessation of AI therapy (0.4 %)
and other (0.6 %). Thirty-one patients had at least one
protocol violation, majorly because of failure to adhere
Table 1 Baseline characteristics
Parameter (N = 486)
Weight (kg) N (missing) 486 (0)
Mean (SD) 59.8 (8.93)
Median 59.0
Min ~max 35,105
Height (cm) N(missing) 486 (0)
Mean (SD) 159.4 (4.58)
Median 160.0
Min ~max 143,175
BMI (kg/m2) N(missing) 486 (0)





Activities limited 148 (30.5 %)
Normal activities 329 (67.7 %)
Bedridden time≤ 50 % 9 (1.9 %)
Total 486 (100.0 %)
Primary site Right breast 240 (49.4 %)
Left breast 243 (50.0 %)
Left breast, right breast 3 (0.6 %)
Total 486 (100.0 %)
Histological type Invasive carcinoma 463 (95.3 %)
Carcinoma in-situ 23 (4.7 %)
Total 486 (100.0 %)
Histological grading Unevaluable(GX) 58 (11.9 %)
Poorly differentialted(G3) 84 (17.3 %)
Well differentiated(G1) 56 (11.5 %)
Undifferentiated(G4) 9 (1.9 %)
Moderately differentiated(G2) 279 (57.4 %)
Total 486 (100.0 %)
ER status Positive 471 (96.9 %)
Negative 15 (3.1 %)
Total 486 (100.0 %)
PR status Positive 387 (79.6 %)
Negative 99 (20.4 %)
Total 486 (100.0 %)
ER and PR status ER positive,PR positive 372 (76.5 %)
ER positive,PR negative 99 (20.4 %)
ER negative,PR positive 15 (3.1 %)
Total 486 (100.0 %)
Mastectomy No 36 (7.4 %)
Yes 450 (92.6 %)
Total 486 (100.0 %)
Breast-conserving
surgery
No 450 (92.6 %)
Table 1 Baseline characteristics (Continued)
Yes 36 (7.4 %)
Total 486 (100.0 %)
Axillary lymph node
dissection
No 103 (21.2 %)
Yes 383 (78.8 %)
Total 486 (100.0 %)
Axillary lymph node
sampling
No 312 (64.2 %)
Yes 174 (35.8 %)
Total 486 (100.0 %)
Prior chemotherapy No 227 (46.7 %)
Yes 259 (53.3 %)
Total 486 (100.0 %)
Prior radiotherapy No 432 (88.9 %)
Yes 54 (11.1 %)
Total 486 (100.0 %)
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to inclusion criteria pertaining to postmenopausal women
aged ≤70 years (n = 21), starting of AI adjuvant therapy
within the past 7 days (n = 7), and unavailability of FACT-
B data for clinical visits 2–5 (n = 8). Subsequently, a total
of 486 patients (98.4 %) were included for the final analysis
(Fig. 1).
Demographics and other baseline characteristics
All the 486 patients were of Chinese ethnic origin with a
mean age of 57.3 years (range: 27–79 years), including
316 (65 %) women aged ≤60 years and 170 (35 %)
women aged >60 years. Other baseline characteristics
are listed in Table 1. Most patients had unilateral breast
cancer, except three patients who reported bilateral pri-
mary breast cancer. More than half (372; 76.5 %) of the
patients had estrogen receptor (ER, +)/progesterone re-
ceptor (PR, +) breast cancer, 99 (20.4 %) patients had
ER(+)/PR(−) breast cancer, and 15 (3.1 %) patients had
ER(−)/PR(+) breast cancer.
A total of 450 (92.6 %) patients had mastectomy, 36
(7.4 %) had breast-conserving surgery, 383 (78.8 %) had
axillary lymph-node dissection, and 312 (64.2 %) had
undergone axillary lymph-node sampling. Fifteen pa-
tients had an unknown AI use status; 426 patients were
taking anastrozole, with 416 (97.7 %) treated for more
than 2 years. The detailed information is given in Table 2.
Among the 486 patients, only 1 patient reported hor-
mone replacement therapy, 152 (31.3 %) patients were
found to have major medical conditions other than breast
cancer, and 92 (18.9 %) patients had major surgical therap-
ies other than breast cancer surgery.
Primary endpoint-change in the FACT-B TOI from baseline
to 24 months
A significant improvement was observed on the mean
FACT-B TOI from baseline (mean: 90.69) to 24 months
(mean: 98.72; P < .0001) (Table 3). In the MIXED model,
baseline TOI, visit, prior chemotherapies, age group, and
axillary lymph-node dissection presented statistically sig-
nificant effects on the change of FACT-B TOI; however,
mastectomy presented no statistically significant effects
on the change of FACT-B TOI (Table 4). Lower boundary
of the CI of the least squares (LS) mean (adjusted mean)




(N = 486) n (%)







Anastrozole/exemestane >24 1 (100)
Total 1 (100)
Anastrozole/letrozole >24 5 (100)
Total 5 (100)
Exemestane >24 10 (100)
Total 10 (100)
Letrozole 6–12 2 (6.9)
>24 27 (93.1)
Total 29 (100)
Table 3 FACT-B TOI at each post-treatment visit and changes
from baseline (final analysis set)
Final analysis set (N = 486)
Visit Clinical efficacy TOI TOI change from
baseline
Baseline N (missing) 486 (0)
Mean (SD) 90.69 (19.526)
Median 89.65
Min–max 31.3–137.0
6 months N (missing) 480 (6) 480 (6)
Mean (SD) 94.36 (18.995) 3.58 (15.312)
Median 94.00 1.50
Min–max 58.5–141.0 −61.0 to 61.8
P value in comparison
to baseline
<.0001
12 months N (missing) 483 (3) 483 (3)
Mean (SD) 97.71 (20.670) 7.03 (19.241)
Median 98.00 3.83
Min–max 47.0–140.0 −50.0 to 82.0
P value in comparison
to baseline
<.0001
18 months N (missing) 447 (39) 447 (39)
Mean (SD) 96.75 (22.074) 5.18 (21.378)
Median 95.83 4.00
Min–max 54.0–142.0 −58.0 to 78.0
P value in comparison
to baseline
<.0001
24 months N (missing) 436 (50) 436 (50)
Mean (SD) 98.72 (22.672) 7.51 (22.476)
Median 97.58 6.00
Min–max 49.0–140.0 −59.0 to 81.3
P value in comparison
to baseline
<.0001
FACT-B Functional Assessment of Cancer Therapy-Breast, SD standard deviation,
TOI trial outcome index
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change from baseline to 24 months in FACT-B TOI was
>0, indicative of an increased TOI at 24 months of treat-
ment. Moreover, LS mean change from 6 to 24 months of
treatment was −4.48 (P < .0001). The LS mean of changes
from baseline in FACT-B TOI with 95 % CIs is given in
Table 4.
Secondary end points
Changes in the FACT-B TOI from baseline to 6, 12, and
18 months
The mean FACT-B TOI was 90.69, 94.36, 97.71, and
96.75 at baseline, 6, 12, and 18 months, respectively,
contributing to the increases from baseline 3.58, 7.03,
and 5.18 at 6, 12, and 18 months, respectively (Table 3).
The mean change in FACT-B TOI was significant at all
time points as compared with baseline (P < .0001, for all).
Changes in the FACT-B EWB from baseline to 6, 12, 18, and
24 months
The mean FACT-B EWB was 16.32, 16.55, 17.34, 17.47,
and 17.85 at baseline, 6, 12, 18, and 24 months, respect-
ively, contributing to the mean increases from baseline
0.18, 1.03, 0.90, and 1.36 at 6, 12, 18, and 24 months,
respectively (Table 5). The mean change in FACT-B
EWB was significant at 12, 18, and 24 months as com-
pared with baseline (P < .0001, for all).
In the MIXED model, baseline TOI, clinical visit, and
prior chemotherapies had statistically significant effects
on the change in FACT-B TOI, whereas age group,
mastectomy, and axillary lymph-node dissection had no
statistically significant effects on the change in FACT-B
EWB (Table 6). In the MIXED model including baseline
TOI, clinical visit, prior chemotherapies, age group,
mastectomy, and axillary lymph-node dissection, the
lower boundaries of the CIs of the LS mean (adjusted
mean) changes from baseline to 12, 18, and 24 months
in FACT-B EWB were all >0, indicating increased scores
at 12, 18, and 24 months of treatment. The changes
from 6 months of treatment to 12, 18, and 24 months of
treatment are detailed in Table 6.
Changes in the FACT-B SWB from baseline to 6, 12, 18, and
24 months
The mean FACT-B SWB was 18.61, 19.14, 19.35, 18.32,
and 18.40 at baseline, 6, 12, 18, and 24 months, respect-
ively, contributing to the mean changes from baseline
Table 4 LS mean of changes from baseline in FACT-B TOI with 95 % CIs (final analysis set)
Final analysis set (N = 486)
LS Mean 95 % CI P value
Visit 6 months 4.04 1.64–6.43 –
12 months 7.10 4.57–9.63 –
18 months 6.54 3.84–9.25 –
24 months 8.51 5.75–11.27 –
6–12 months −3.06 −4.06 to −2.06 <.0001
6–18 months −2.50 −3.83 to −1.17 .0002
6–24 months −4.48 −5.96 to −2.99 <.0001
12–18 months 0.56 −0.59 to 1.70 .3405
12–24 months −1.41 −2.78 to −0.05 .0422
18–24 months −1.97 −2.92 to −1.02 <.0001
Prior chemotherapies Yes 10.99 8.20–13.77 –
No 2.11 −0.69 to 4.90 –
Yes–No 8.88 6.36–11.40 <.0001
Age group >60 years 8.04 5.04–11.05 –
≤60 years 5.05 2.44–7.66 –
>60 to ≤60 years 2.99 0.37–5.61 .0256
Mastectomy Yes 7.63 5.88–9.38 –
No 5.46 0.90–10.03 –
Yes–No 2.17 −2.63 to 6.97 .3752
Axillary lymph-node dissection Yes 4.77 2.00–7.55 –
No 8.32 5.22–11.43 –
Yes–No −3.55 −6.68 to −0.41 .0268
CI confidence interval, FACT-B Functional Assessment of Cancer Therapy-Breast, LS least squares, TOI trial outcome index
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0.54, 0.75, −0.45, and −0.19 at 6, 12, 18, and 24 months,
respectively. The mean change in FACT-B SWB was sig-
nificant at 6 months (P < .0435) and 12 months (P < .0086)
as compared with the baseline value (Table 7). In the
MIXED model, baseline TOI, clinical visit, prior chemo-
therapies, age group, and axillary lymph-node dissection
presented statistically significant effects on the FACT-B
SWB, whereas mastectomy presented no statistically
significant effects on the FACT-B SWB. The LS means
of changes from baseline in the FACT-B SWB score
with 95 % CI are presented in Table 8.
Discussion
This first prospective, multicenter, observational, and
non-interventional study in Chinese postmenopausal
women with HR (+) breast cancer or HR+ EBC undergo-
ing adjuvant treatment with AIs demonstrated significant
improvements in the long-term QoL when evaluated at 6,
12, 18, and 24 months post-AI treatment. The study will
provide insight to the concerns of the survivors and
convey the information to clinical decision-makers who
can use it to create patient-centered solutions.
Shen et al. [15] conducted a clinical controlled study
in 522 patients to investigate the QoL of Chinese women
with breast cancer by using the FACT-B scale. Regres-
sion analysis demonstrated that there was a significant
increase in FACT-B TOI of the patients >50 years of
age, with low-stage cancer, and with high education and
income. This was a cross-sectional, single-center obser-
vational study in Chinese patients that provided valuable
information about factors affecting the QoL of Chinese
women with breast cancer. However, dynamic changes
on the long-term QoL were not assessed.
Mixed results have been obtained from previous studies
conducted on the HRQoL outcomes following AI therapy.
Some studies have suggested that treatment with AIs
may improve QoL, whereas others have indicated no
increased benefit in HRQoL with AI compared with
tamoxifen [16]. Fallowfield et al. first published results
from a longitudinal follow-up of the impact of 5 years
Table 5 FACT-B EWB scores at each post-treatment visit and changes from baseline (final analysis set)
Final analysis set (N = 486)
Visit Clinical efficacy Total score Change from baseline in total score
Baseline N (missing) 486 (0)
Mean (SD) 16.32 (4.497)
Median 17.00
Min–max 2.0–24.0
6 months N (missing) 480 (6) 480 (6)
Mean (SD) 16.55 (4.318) 0.18 (3.741)
Median 17.00 0.00
Min–max 6.0–24.0 −13.0 to 12.0
P value in comparison to baseline 0.2846
12 months N (missing) 483 (3) 483 (3)
Mean (SD) 17.34 (4.083) 1.03 (4.314)
Median 17.00 1.00
Min–max 6.0–24.0 −11.0 to 17.0
P value in comparison to baseline <.0001
18 months N (missing) 447 (39) 447 (39)
Mean (SD) 17.47 (4.215) 0.90 (4.600)
Median 18.00 1.00
Min–max 0.0–24.0 −12.0 to 17.0
P value in comparison to baseline <.0001
24 months N (missing) 436 (50) 436 (50)
Mean (SD) 17.85 (4.163) 1.36 (5.027)
Median 18.00 1.00
Min–max 0.0–24.0 −14.0 to 16.0
P value in comparison to baseline <.0001
EWB emotional well-being, FACT-B Functional Assessment of Cancer Therapy-Breast, SD standard deviation
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of adjuvant AI (anastrozole) and tamoxifen (alone/com-
bination) treatment on HRQoL in a subgroup of 1105
patients (ATAC) [12]. Improvement in TOI was com-
parable in both the treatment groups over the 5-year
recommended adjuvant treatment period [11, 12].
A 5-point increase in the FACT-B TOI is considered
as a significant clinical benefit [17, 18]. The results of our
current analysis are in line with those of the above-
mentioned studies and demonstrated a significant increase
of more than 5 points from baseline (mean: 90.69) to
24 months (mean: 98.72; P < .0001), thereby indicating sig-
nificant clinical benefit of adjuvant AIs endocrine therapy
in the QoL of patients with breast cancer.
Kwan et al. [19] demonstrated that the improvement
of FACT-B TOI score in elderly patients (>60 years of
age) was better than that in young patients. In addition,
ATAC study demonstrated improvement of FACT-B
TOI score in patients with previous chemotherapy than
in those with no previous chemotherapy [12]. Our find-
ings are in line with these two studies. The findings
showed significant effects of all of these factors, except
for mastectomy, on the changes in FACT-B TOI scores.
Further exploratory analysis also showed that the TOI
for the previous chemotherapy patient group >60 years
of age without axillary lymph-node dissection was signifi-
cantly improved from the baseline value. Additionally, ef-
fects of baseline score, follow-up, and prior chemotherapy
on changes in FACT-B EWB subscale scores were signifi-
cant, whereas the effects of age group, mastectomy, and
axillary lymph-node dissection were not significant. We
prospectively set the two subscales of FACT-B, i.e. EWB
and SWB as secondary endpoints. We considered that
EWB and SWB are more important to women compared
with other subscales for the breast cancer, as they serve as
an individual resource for dealing with illness and attuning
to uncertainties related with chronic illness. It can also
affect a woman’s self-esteem or may have psychological
impact as a result of breast cancer. There were significant
effects of baseline score, follow-up, previous chemother-
apy, age group, and axillary lymph-node dissection on
changes in FACT-B SWB subscale scores, but mastectomy
had no significant effect. Although studies have analyzed
the HRQoL outcomes following AI treatment, a definitive
comprehensive conclusion on long-term HRQoL is still
Table 6 LS mean of changes from baseline in FACT-B EWB score with 95 % CIs (final analysis set)
Final analysis set (N = 486)
LS mean 95 % CI P value
Follow-up 6 months −0.00 −0.53 to 0.53 –
12 months 0.76 0.22–1.30 –
18 months 0.92 0.36–1.48 –
24 months 1.29 0.71–1.86 –
6–12 months −0.76 −1.04 to −0.48 <.0001
6–18 months −0.92 −1.26 to −0.58 <.0001
6–24 months −1.29 −1.65 to −0.93 <.0001
12–18 months −0.16 −0.46 to 0.14 .2895
12–24 months −0.53 −0.88 to −0.18 .0033
18–24 months −0.37 −0.67 to −0.07 .0172
Prior chemotherapies Yes 1.54 0.96–2.12 –
No −0.06 −0.64 to 0.53 –
Yes–No 1.60 1.05–2.14 <.0001
Age group >60 years 1.01 0.38–1.64 –
≤60 years 0.47 −0.07–1.01 –
>60 years – ≤60 years 0.54 −0.03 to 1.10 .0613
Mastectomy Yes 1.20 0.85–1.55 –
No 0.29 −0.68 to 1.25 –
Yes–No 0.91 −0.12 to 1.94 .0823
Axillary lymph-node dissection Yes 0.48 −0.10 to 1.06 –
No 1.01 0.36–1.65 –
Yes–No −0.53 −1.20–0.14 .1233
CI confidence interval, EWB emotional well-being, FACT-B Functional Assessment of Cancer Therapy-Breast, LS least squares
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lacking in China. Several unresolved issues still prevent
clinicians from designing an optimal endocrine therapy
for postmenopausal women with EBC. Thus, the current
study provides reinforcement to the previous findings and
indicates improved long-term QoL with AI treatment.
This will aid clinicians in optimizing treatment to yield ef-
fective healthcare outcomes.
Our results were different from those of ATAC and
the Intergroup Exemestane Study (IES) substudy, which
may be probably because of the following factors: (1)
culture background: after treatment, American women
with breast cancer were more likely to feel a loss of per-
sonal image, intimacy, and sex life than East Asian
women [20, 21]; (2) study population: although the pa-
tients in ATAC, IES, and this study were menopausal
women, there was no clear definition of “menopause” in
the relevant published literature; therefore, it cannot be
confirmed whether the definition was consistent with
that in NCCN-Breast Cancer Version 2013 ( having pre-
vious bilateral oophorectomy; ≥60 years of age; <60 years
of age having experienced amenorrhea for more than
12 months with no chemotherapy, tamoxifen, toremi-
fene, or ovariectomy and follicle-stimulating hormone
(FSH) and estradiol within menopausal range; <60 years
of age having taken tamoxifen or toremifene, and FSH
and plasma estradiol within menopausal range). Women
≤60 years of age accounted for only 33.7 % in the IES
study, whereas women ≤60 years of age accounted for
65.0 % in this study.
Finally, the inherent limitations of this study should
not be neglected. The study had neither a control or a
standard group nor a blinding design. It is well known
that a standard endocrine therapy for breast cancer
would continue for at least 5 years; however, in the
current study, all but 1 patient received the initial hor-
monal therapy at baseline and the follow-up was only
for 2 years. Therefore, the effect of endocrine therapy on
3- to 5-year long-term QoL remains unknown. The
aforementioned limitations indicate that this study only
recognizes the significant improvements in the long-
Table 7 FACT-B SWB scores at each post-treatment visit and changes from baseline (final analysis set)
Final analysis set (N = 486)
Visit Clinical efficacy Total score Change from baseline in total score
Baseline N (missing) 486 (0)
Mean (SD) 18.61 (6.732)
Median 19.30
Min–max 0.0–28.0
6 months N (missing) 480 (6) 480 (6)
Mean (SD) 19.14 (6.068) 0.54 (5.872)
Median 19.83 0.00
Min–max 0.0–28.0 −24.5 to 28.0
P value in comparison to baseline .0435
12 months N (missing) 483 (3) 483 (3)
Mean (SD) 19.35 (6.531) 0.75 (6.245)
Median 20.00 0.00
Min–max 0.0–28.0 −21.3 to 28.0
P value in comparison to baseline .0086
18 months N (missing) 447 (39) 447 (39)
Mean (SD) 18.32 (6.900) −0.45 (6.605)
Median 19.00 0.00
Min–max 0.0–28.0 −20.0 to 28.0
P value in comparison to baseline 0.1523
24 months N (missing) 436 (50) 436 (50)
Mean (SD) 18.40 (7.422) −0.19 (6.961)
Median 19.83 0.00
Min–max 1.0–28.0 −21.0 to 28.0
P value in comparison to baseline 0.5677
FACT-B Functional Assessment of Cancer Therapy-Breast, SD standard deviation, SWB social well-being
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term QoL (6, 12, 18, and 24 months) of postmenopausal
Chinese patients with HR+ EBC after starting treatment
with AIs and does not provide a robust association be-
tween improvement of QoL scores ande treatment with
AIs. Generally, observational studies have the benefit of
assessing multiple aspects of lifestyle and better repre-
sent the results; however, potential limitation of selection
bias and reporting of scores may have confounded the
overall results in this study. We also did not assess the
side effects of the treatment by aromatase inhibitors in
this population. We had not systematically recorded the
safety profile during the study execution and retrospect-
ive safety recall would have bias. Taken together, our
study results showed the dynamic change of FACT-B,
which will guide the physicians to communicate with
the HR+ EBC patients about the QOL when receiving
adjuvant AIs. Also, the improved QoL will increase pa-
tient compliance during the study treatment.
Conclusions
The present study demonstrated significant improve-
ments in the long-term QoL of postmenopausal patients
with EBC at 6, 12, 18, and 24 months after starting
treatment with AIs compared with baseline values. Based
on results from the MIXED model (for data collection at
6, 12, and 18 months), we found significant effects of base-
line score, follow-up, previous chemotherapy, age group,
and axillary lymph-node dissection on changes in FACT-B
TOI score and SWB scores, as well as significant effects of
baseline score, follow-up, and previous chemotherapy on
changes in FACT-B EWB scores. However, there were
no significant effects of mastectomy on changes in TOI,
SWB, or EWB scores. Further comparative work should
be undertaken to strengthen the findings from this study.
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Table 8 LS mean of changes from baseline in FACT-B SWB score with 95 % CIs (final analysis set)
Final analysis set (N = 486)
LS mean 95 % CI P value
Follow-up 6 months 0.85 0.07–1.63 –
12 months 1.02 0.23–1.80 –
18 months 0.13 −0.69 to 0.95 –
24 months 0.22 −0.62 to 1.07 –
6–12 months −0.16 −0.63 to 0.30 .4849
6–18 months 0.72 0.21–1.23 .0057
6– 24 months 0.63 0.05–1.20 .0323
12–18 months 0.89 0.49–1.28 <.0001
12–24 months 0.79 0.27–1.31 .0029
18–24 months −0.09 −0.51 to 0.32 .6622
Prior chemotherapies Yes 1.75 0.90–2.61 -
No −0.64 −1.49 to 0.21 -
Yes–No 2.40 1.60-3.19 <.0001
Age group >60 years 1.30 0.39–2.22 –
≤60 years −0.19 −0.99 to 0.60 –
>60 to ≤60 years 1.50 0.68–2.32 .0004
Mastectomy Yes 0.72 0.21–1.24 –
No 0.39 −1.02 to 1.79 –
Yes–No 0.33 −1.16 to 1.83 .6596
Axillary lymph-node dissection Yes 0.06 −0.78 to 0.90 –
No 1.05 0.10–2.00 –
Yes–No −0.99 −1.97 to −0.01 .0482
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